Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0045 | 0 | 0.5 |
Plasmodium falciparum | glutathione reductase | 0.0129 | 1 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0129 | 1 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0129 | 1 | 1 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0045 | 0 | 0.5 |
Toxoplasma gondii | thioredoxin reductase | 0.0129 | 1 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0045 | 0 | 0.5 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0045 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0045 | 0 | 0.5 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0129 | 1 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0129 | 1 | 1 |
Trypanosoma brucei | trypanothione reductase | 0.0129 | 1 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0129 | 1 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.0129 | 1 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0129 | 1 | 1 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0045 | 0 | 0.5 |
Leishmania major | trypanothione reductase | 0.0129 | 1 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0129 | 1 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0045 | 0 | 0.5 |
Treponema pallidum | NADH oxidase | 0.0045 | 0 | 0.5 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0045 | 0 | 0.5 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0129 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0045 | 0 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.0129 | 1 | 1 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0045 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.